Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537
3 October 2022. Related: Antiretrovirals.
Antiretrovirals
Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence
3 October 2022. Related: Antiretrovirals, Drug resistance.
Lenacapavir approved in the EU and UK to treat multidrug resistant HIV
1 September 2022. Related: Antiretrovirals.
Dolutegravir-based ART in children and adolescents: effective in six African countries
3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Early data on injecting CAB/RPV-LA into thigh muscle
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Simplifed lenacapavir dosing: PK results in HIV negative study
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Lenacapavir gets positive opinion for approval in the EU to treat MDR HIV
1 July 2022. Related: Antiretrovirals.
Combination bNAb’s sustain viral suppression for 40 weeks: phase 1 results
1 July 2022. Related: Antiretrovirals, Cure-related research.
Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published
1 June 2022. Related: Antiretrovirals.
ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
FDA approves dispersible dolutegravir/abacavir/3TC for children
2 May 2022. Related: Antiretrovirals.
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits
2 May 2022. Related: Antiretrovirals, Treatment access.
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals.
US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents
1 April 2022. Related: Antiretrovirals.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques
1 March 2022. Related: Conference reports, Antiretrovirals.
US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine
7 February 2022. Related: Antiretrovirals.
Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent
7 February 2022. Related: Antiretrovirals.
Selected islatravir studies stop enrolment: further complications with important investigational drugs
20 December 2021. Related: Antiretrovirals.
FDA further limits use of islatravir in ongoing studies
20 December 2021. Related: Antiretrovirals.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks
30 November 2021. Related: Conference reports, Antiretrovirals.
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
30 November 2021. Related: Conference reports, Antiretrovirals.
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales
30 November 2021. Related: Antiretrovirals, Treatment access.
MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring
30 November 2021. Related: Antiretrovirals.
NHS Scotland approves long-acting cabotegravir and rilpivirine injections
31 October 2021. Related: Antiretrovirals.
Lenacapavir submitted to EMA for MDR HIV
17 September 2021. Related: Antiretrovirals.
Pipeline report 2021: HIV drugs in development
17 September 2021. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide
1 August 2021. Related: Conference reports, Antiretrovirals.
Lenacapavir submitted to FDA as long-acting treatment for MDR HIV
1 July 2021. Related: Antiretrovirals.
CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP
1 April 2021. Related: Conference reports, Antiretrovirals.
Gilead and Merck/MSD to collaborate on long-acting HIV combination of lenacapavir and islatravir
1 April 2021. Related: Antiretrovirals.
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
12 March 2021. Related: Conference reports, Antiretrovirals.
US FDA approves long-acting injectable HIV treatment: monthly dosing
22 January 2021. Related: Antiretrovirals.
Long-acting injectable HIV treatment approved in the EU: includes two-monthly dosing
22 January 2021. Related: Antiretrovirals.
Fostemsavir approved in the EU (Rukobia): NICE deferred in the UK
22 January 2021. Related: Antiretrovirals.
EU approves dolutegravir 5 mg dispersible for children older than four weeks
9 December 2020. Related: Antiretrovirals, Paediatric care.
New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year
9 December 2020. Related: Antiretrovirals, Treatment access, Paediatric care.
New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet
11 November 2020. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
EMA issues positive opinion to approve cabotegravir LA/rilpivirine LA injections (Vocabria/Rekambys) as new HIV treatment
11 November 2020. Related: Antiretrovirals.
Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes
14 October 2020. Related: Conference reports, Antiretrovirals.
Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg
14 October 2020. Related: Conference reports, Antiretrovirals.
Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing
28 August 2020. Related: Conference reports, Antiretrovirals.
US FDA approves dolutegravir/lamivudine (Dovato) as switch option
28 August 2020. Related: Antiretrovirals.
EMA extends indication for darunavir/r to include adolescents >12 years
28 August 2020. Related: Antiretrovirals.
ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva, Vocabria) to FDA for approval
28 August 2020. Related: Antiretrovirals.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau
22 July 2020. Related: Conference reports, Antiretrovirals.
FDA approves fostemsavir (Rukobia) for multidrug resistant HIV in the US
22 July 2020. Related: Antiretrovirals.
FDA approves dolutegravir formulations to treat infants and young children
26 June 2020. Related: Antiretrovirals, Paediatric care.
Fit for purpose: antiretroviral treatment optimisation March 2020
12 March 2020. Related: Special reports, Supplements, Fit for purpose, Antiretrovirals.
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
12 March 2020. Related: Conference reports, Antiretrovirals.
Long-acting cabotegravir and rilpivirine: similar results in women and men
24 February 2020. Related: Conference reports, Antiretrovirals, Women's health.
FDA decision on long-acting cabotegravir/rilpivirine (Cabenuva, Vocabria) injections delayed due to scale-up manufacturing problems
29 January 2020. Related: Antiretrovirals.
Fostemsavir submitted to EMA for treating multidrug resistant HIV
29 January 2020. Related: Antiretrovirals.
Gilead announces licensing agreement for Rockefeller University bNAbs
29 January 2020. Related: Antiretrovirals.
Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV
13 December 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine as dual ART
13 December 2019. Related: Conference reports, Antiretrovirals.